Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference

Rhea-AI Summary

Fusion Pharmaceuticals (NASDAQ: FUSN), a clinical-stage oncology company, has announced a presentation at the Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023, at 3:00 p.m. ET. The presentation will be delivered by John Valliant, Ph.D., the Chief Executive Officer. Investors can access a live webcast of the presentation on the Company's website, with a replay available for 90 days.

Fusion specializes in developing next-generation radiopharmaceuticals, aiming to deliver targeted cancer therapies. Their clinical pipeline includes several trials targeting various cancers, including those resistant to traditional therapies. Recent collaborations with AstraZeneca and Merck highlight Fusion's commitment to advancing cancer treatment through innovative approaches.

HAMILTON, ON and BOSTON, April 20, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present in a company presentation at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 25, 2023 at 3:00 p.m. ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.  

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following their respective presentation dates.

About Fusion

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules to selectively deliver the alpha emitting payloads to tumors. Fusion's clinical portfolio includes: FPI-2265 targeting prostate specific membrane antigen (PSMA) for metastatic castration resistant prostate cancer currently in a Phase 2 trial; FPI-1434 targeting insulin-like growth factor 1 receptor currently in a Phase 1 trial; FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), currently in a Phase 1 trial; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1), currently in a Phase 1 trial. In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Response Inhibitors (DDRis) and immuno-oncology agents. The Company recently received IND clearance for the first novel TAT under the collaboration, which targets EGFT-cMET. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. To support Fusion's growing pipeline of TATs, the Company has signed strategic actinium supply agreements with TRIUMF, Niowave, Inc. and BWXT Medical.

Contact:

Amanda Cray
Senior Director of Investor Relations & Corporate Communications
(617) 967-0207
cray@fusionpharma.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-bloom-burton--co-healthcare-investor-conference-301803540.html

SOURCE Fusion Pharmaceuticals

FAQ

When will Fusion Pharmaceuticals present at the Bloom Burton & Co. Healthcare Investor Conference?

Fusion Pharmaceuticals will present on April 25, 2023, at 3:00 p.m. ET.

Who will present for Fusion Pharmaceuticals at the conference?

The presentation will be made by John Valliant, Ph.D., the Chief Executive Officer.

How can I watch the Fusion Pharmaceuticals presentation?

The presentation will be available via a live webcast on Fusion’s 'Events and Presentations' page of their website.

What is the focus of Fusion Pharmaceuticals' clinical pipeline?

Fusion Pharmaceuticals focuses on developing next-generation radiopharmaceuticals targeting various cancers.

What collaborations has Fusion Pharmaceuticals recently entered into?

Fusion has collaborations with AstraZeneca and Merck to develop targeted cancer therapies.